These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30887764)

  • 21. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
    Ismail MT; Fahmy DM; Elshmaa NS
    Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
    Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
    Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives.
    Shen ZQ; Zhu HT; Lin JF
    Obstet Gynecol; 2008 Aug; 112(2 Pt 2):465-7. PubMed ID: 18669766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
    Baker J; Obermair A; Gebski V; Janda M
    Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA).
    Voigt LF; Deng Q; Weiss NS
    Cancer Causes Control; 1994 May; 5(3):227-33. PubMed ID: 8061170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 4. Effects on uterine and cervical epithelia.
    Bastianelli C; Farris M; Bruni V; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):163-182. PubMed ID: 31975619
    [No Abstract]   [Full Text] [Related]  

  • 28. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia.
    Lowe MP; Cooper BC; Sood AK; Davis WA; Syrop CH; Sorosky JI
    Gynecol Oncol; 2003 Dec; 91(3):569-72. PubMed ID: 14675678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endometrial hyperplasia as a risk factor of endometrial cancer.
    Nees LK; Heublein S; Steinmacher S; Juhasz-Böss I; Brucker S; Tempfer CB; Wallwiener M
    Arch Gynecol Obstet; 2022 Aug; 306(2):407-421. PubMed ID: 35001185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood.
    Hancock DB; Håberg SE; Furu K; Whitworth KW; Nafstad P; Nystad W; London SJ
    Pediatr Allergy Immunol; 2011 Aug; 22(5):528-36. PubMed ID: 21294776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.
    Epplein M; Reed SD; Voigt LF; Newton KM; Holt VL; Weiss NS
    Ann Epidemiol; 2009 Jan; 19(1):1-7. PubMed ID: 19064186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fertility outcomes in infertile women with complex hyperplasia or complex atypical hyperplasia who received progestin therapy and in vitro fertilization.
    Li M; Song JL; Zhao Y; Wu SL; Liu HB; Tang R; Yan L
    J Zhejiang Univ Sci B; 2017 Nov.; 18(11):1022-1025. PubMed ID: 29119739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
    Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
    Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
    Emarh M
    Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.